A Randomized, Double-blind, Double-dummy, Placebo Controlled, Single-Dose, 6-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Orally to Non-Dependent, Recreational Opioid Users
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Oxycodone/naltrexone (Primary) ; Oxycodone
- Indications Pain
- Focus Pharmacodynamics
- Sponsors Pfizer
- 03 May 2014 Primary endpoints 'drug liking and high measured on visual analog scales, reported as Emax and AUE0-2h from 0 to 2 hours' has been met as per the results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
- 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History